Jennifer Doudna’s research has transformed biology. And this is not an understatement. Her work has given us the tools to edit genes more precisely than ever before.
It is challenging to determine the composition of a given ribonucleoprotein. We recently approached this problem by adapting the original RNA interactome capture protocol (Castello et al., Cell 2012), to the use of specific antisense LNA probes to capture specific RNA species. We use this method to elucidate the composition of luciferase containing reporters and ribosomal RNA in vitro and in vivo. We were able to recapitulate well-established protein-RNA interactions and to discover new ones.
Specific RNP capture with antisense LNA/DNA mixmers. Rogell B, Fischer B, Rettel M, Krijgsveld J, Castello A, Hentze MW. RNA. 2017 Aug;23(8):1290-1302. doi: 10.1261/rna.060798.117. Epub 2017 May 5.
Our colleague Vicent Pelechano is looking for a postdoc in Genomics/Computational Biology to join his team at Karolinska Institutet – SciLifeLab.
The available postdoctoral position concerns developing and applying novel genomic and computational approaches to study ribosome dynamics and RNA metabolism, and its impact to cell-to-cell phenotypic heterogeneity. The candidate will focus on the computational analysis of newly developed methods to study ribosome dynamics, mRNA degradation and tRNA processing (e.g. Pelechano et al. Cell 2015). The candidate is expected to contribute to our common goal of understanding how RNA biology and post-transcriptional regulation contributes to the appearance of differences across clonal populations of cells.
The application deadline is October 2nd and you can find more information about this job here: http://pelechanolab.com/2017/06/21/postdoctoral-stipend-in-genomics-computational-biology/
We are back from the RNA2107 in Prague. Very exciting talks!
One highlight, Adrian Krainer talked about SPINRAZA, a new therapy against spinal muscular atrophy (SMA) based on antisense oligos. SMA produces the loss of motor neurons that ends up in muscle wasting and early dead (the life expectation of a new born baby with type 1 SMA is ten months). The recently developed treatment treatment has shown excellent results in phase III clinical trials. Adrian guided us through the conception and development of the drug and included emotive videos of how SPINRAZA improves the life of children affected with SMA. An inspiring talk that demonstrates that basic science is fundamental for advancing applied research.